COVID-19: ACR issues pediatric guidance
Updated 10 August 2020
medwireNews: The American College of Rheumatology (ACR) has issued two clinical guidance documents for the management of pediatric patients during the COVID-19 pandemic.
The first provides recommendations for pediatric rheumatologists on the management of children with rheumatic diseases, including guidance on minimizing SARS-CoV-2 infection risk, and when to start, stop, or reduce their medications. The guidance covers various situations, including the presence and absence of exposure to SARS-CoV-2, asymptomatic infection, and symptomatic COVID-19.
The second guidance document provides direction on the management of inflammatory syndromes associated with SARS-CoV-2 infection in children and adolescents, and addresses multisystem inflammatory syndrome in children (MIS-C), a condition characterized by inflammation, fever, and multiorgan dysfunction that can occur late in the COVID-19 disease course.
The guidance advises on the diagnosis of MIS-C, discusses the similarities and differences relative to Kawasaki disease, and provides recommendations on cardiac management, immunomodulatory treatment, and antiplatelet and anticoagulation therapy.
Both guidance documents have been published as "living documents" in Arthritis & Rheumatology, and will be updated as new evidence emerges.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group
19 June 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.